Bionano Genomics Inc. (BNGO)
undefined
undefined%
At close: undefined
0.24
0.66%
After-hours Dec 13, 2024, 07:20 PM EST

Company Description

Bionano Genomics, Inc. provides genome analysis software solutions.

It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight.

The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics.

In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes.

The company was founded in 2003 and is headquartered in San Diego, California.

Bionano Genomics Inc.
Bionano Genomics Inc. logo
Country United States
IPO Date Aug 21, 2018
Industry Medical - Diagnostics & Research
Sector Healthcare
Employees 344
CEO Dr. Robert Erik Holmlin M.B.A., Ph.D.

Contact Details

Address:
9540 Towne Centre Drive
San Diego, California
United States
Website https://www.bionanogenomics.com

Stock Details

Ticker Symbol BNGO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001411690
CUSIP Number 09075F107
ISIN Number US09075F3055
Employer ID 26-1756290
SIC Code 3826

Key Executives

Name Position
Dr. Robert Erik Holmlin M.B.A., Ph.D. President, Chief Executive Officer & Director and Chief Financial Officer
Mark Oldakowski Chief Operating Officer
Cory Kreeck Global Head of People Operations
Donna Polizio Global Head of Market Access
Dr. Alka Chaubey FACMG, Ph.D. Chief Medical Officer
Jonathan Dixon J.D. General Counsel & Secretary
Mark Adamchak CPA Vice President of Accounting & Controller
Stanislas Marin M.B.A., M.S. Vice President of Global Sales

Latest SEC Filings

Date Type Title
Dec 05, 2024 DEFA14A Filing
Dec 05, 2024 DEF 14A Filing
Dec 02, 2024 8-K Current Report
Nov 25, 2024 PRE 14A Filing
Nov 14, 2024 10-Q Quarterly Report
Nov 13, 2024 8-K Current Report
Oct 31, 2024 8-K Current Report
Oct 31, 2024 424B5 Filing
Oct 31, 2024 DEFA14A Filing
Oct 10, 2024 8-K Current Report